FDA Talks about Supply Chain Challenges - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Talks about Supply Chain Challenges
Pharmaceutical Technology has summarized recent statements by FDA officials on supply chain issues to provde the agency's most up-to-date views and expectations.


Pharmaceutical Technology


Globalization's impact

-Janet Woodcock, director, Center for Drug Evaluation and Research (CDER)

"Heparin was a wakeup call," demonstrating that we "need vigilance throughout the supply chain," said Woodcock. Solving these issues is "going to take a lot of harmonization" given the challenges. These challenges include: an explosion of global manufacturing, increased complexity of the supply chain, greater potential for exploitation, a global regulatory system that is still fragmented, US erosion of inspectional coverage, and a lack of modern information technology systems.

"Globalization is taking over as the standard of the day....," added Woodcock. To move forward from here, we need "seamless, effective global regulatory collaboration" with a worldwide safety net and increased effectiveness of inspectorates in developing countries. We also need fully harmonized quality standards in ICH (International Conference on Harmonization) and non-ICH regions, manufacturing modernization, harmonization of pharmacopeial stands, agreed-upon methods for supply-chain security, and better information technology, including better automation and standardization of global inventory.

In terms of responsibility, Woodcock discussed the fact that manufacturers must take responsibility for pharmaceutical quality of their products and for the integrity of their own supply chains. Regulators must adopt standards that ensure a safety net and take actions against poor quality, while enabling continuous improvement. Standards and technical organizations need to reach consensus on technical standards. Professional and technical societies must develop and update standards and disseminate them to industry via educational opportunities.

For its part, said Woodcock, FDA is continuing with its Pharmaceutical Quality for the 21st Century initiative, intensifying its international outreach with programs such as Beyond our Borders, and keeping track of inventory of manufacturing establishments as well as movement of product. More efforts may crystallize after the upcoming presidential election with regard to legislation currently circulating within Congress.

Import safety

-Jeffrey Shuren, associate commissioner for policy and planning, Office of the Commissioner

The Interagency Working Group on Import Safety, established by executive order in July 2007, issued a strategic framework for an Import Safety Action Plan last November. We no longer want a "snapshot at the border, but rather a streaming video feed" of when risk arrives and how we can rapidly respond, said Shuren. The goal is to have a level playing field regarding standards, corporate responsibility, and global partnerships. Companies who are outsourcing or contracting out services need to "trust the 'good actors' but verify their compliance and impose stiff penalties on 'bad actors,'" he said.

According to Shuren, FDA is continuing to work on "good importer practices" guidance, which will be available for comment. Guidance may involve certification of compliance with FDA standards before imports are allowed into the United States.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here